Triglyceride-rich very low density lipoprotein production (VLDL production)

Triglyceride-rich very low density lipoprotein (VLDL) production is a complex physiological process primarily occurring in the hepatocytes, whereby triglycerides, cholesterol, and phospholipids are assembled with apolipoprotein B-100 (ApoB-100) to form VLDL particles. This assembly is critically dependent on the microsomal triglyceride transfer protein (MTP), which acts as a chaperone to load lipids onto the nascent ApoB-100 chain within the endoplasmic reticulum (PubChem CID 135457008). Once assembled, these particles are secreted into the bloodstream to deliver fatty acids to peripheral tissues. Dysregulation of this process, particularly overproduction, is a key driver of hypertriglyceridemia and contributes significantly to the development of atherosclerotic cardiovascular disease (PubMed PMID: 31054366). Therapeutic strategies aimed at reducing VLDL production include MTP inhibitors like Lomitapide and antisense oligonucleotides like Mipomersen, which reduce the availability of ApoB-100. While effective at lowering circulating lipid levels, these interventions can lead to the sequestration of lipids within the liver, potentially causing hepatic steatosis and elevated liver enzymes. Consequently, patients on these therapies often require careful monitoring and dietary modifications to mitigate liver-related safety concerns (FDA Label, Juxtapid).

Other names

VLDL synthesisVLDL secretionHepatic VLDL assemblyVery low-density lipoprotein assembly

Drugs modulate this process through different molecular targets: Lomitapide inhibits the microsomal triglyceride transfer protein (MTP) to prevent the assembly of lipids with ApoB-100; Mipomersen uses antisense technology to inhibit the synthesis of the ApoB-100 protein scaffold itself (NIH StatPearls; PMID: 23635390).